129770761449687500_132As a share of child care and drug industry segment leader, shandahuate (000915) (000915. SZ) since this year's price trend "baby Dragon" concept to benefit relatively obvious. Data show that as of March 23, company's share price closed $ 13.62, gains this year as a 15.52%, and the sameShanghai composite index gained only 6.83%. Qi Jin Shi recently famous cod liver oil brands is aeration of rickets caused by events, in the eyes of analysts, is expected on company subsidiary Dyne pharmaceutical product Yi Kexin (children with vitamin AD drop) sales had a positive impact. As far as I understand, commonly known as calcium deficiency rickets, more common in infancy, is due to vitamin dCaused by lack of calcium and phosphorus metabolism in the body, a disease of poor bone calcification, need to replenish vitamin d rickets, is the Dyne new sales of pharmaceutical products to Iraq's main target group. Qi Lu securities analyst Hu Dejun research described in the report, in the current market for vitamins a, d, shandahuate new shares of more than 50%, is the industry leading brand2011 sales total is expected to exceed 300 million Yuan, brand awareness at the highest in its class. Since last March, "thin", the company's main business areas are mainly for the pharmaceutical and environmental protection industries. 2011 annual report shows, mainly to children's healthcare products company pharmaceutical industry and drug resistance of diabetes, cardiovascular disease
tera gold, digestive system infections such as drug productionAnd sales-friendly chlorine dioxide products are mainly involved in production and sales of equipment and products
tera power leveling, flue gas desulfurization in power plant, energy services, and other services. In 2011, the company's place revenue $ 717 million, an increase of 27.97%, operating profit of $ 176 million, rose 16.22%; $ 94 million in net profit of the shareholders of listed companies of belonging,An increase of 32.9%. Comply with even better than analysts expected.
����Where pharmaceutical products operating income of $ 438 million, an increase of 21.91%, 61.04% per cent of total revenue. Analyst, who asked not to be named, said new capacity release and advertising sales ground effect, is the important reason for the growth of the company. Information shows that the company flagIssued for pharmaceutical new factory completed in December 2010 GMP certification, production in January 2011, to expand production capacity more than 1 time.
����In addition, the company first quarter 2011 began to launch competitive products on television, radio and other media "new" ads. In his view, under the influence of this double effect, the company's pharmaceutical business is expected to continue to merchantGrowth performance aspect of 2012.
����In addition, the company gross profit rate of 85.05% of pharmaceutical products, and sustainable. As Yan Yi Kexin, cover production company flute series, such as child care and drug accumulation of strong brands in the consumer, the company started last year to enter the field of children's food. End of July 2011, company announcements,Dyne pharmacy intended in rongcheng city
tera gold, Shandong province-building children's health food shop. Like-minded analysts said Peng Xiao Gu: "companies involved in child health food industry, and Dyne pharmaceutical industry for improving child health chain, with the help of their good brands, channels and sales network to achieve the harmonious development of children's medicine and health food. "At present, the company hasTry some products through OEM start sales, including probiotic powder, bovine colostrum chewable tablets and ferrous lactate granules.
����Hu Dejun thinks, is expected in 2012 in the test market State, will not pose too much of an impact on the performance of the company, but as the product line constantly enrich, Dyne is expected overall growth performance over the next three years at about 25%. Environmental product revenueImportant component of the performance of the Division. Environmental business of the company involved in flue gas desulfurization equipment, environmental protection, energy saving, and many other areas, 2011 annual revenues of $ 132 million, an increase of 118.05%, 18.92% per cent of total revenue. Relative to the pharmaceutical products, the relatively low level of the gross profit of the business, only 30.9%, and fell a 3.83A percentage point. Risk and drug safety, food safety, risk-friendly business development faces many uncertainties, lack of supporting rapid development of products and technical reserves.
Others:
沒有留言:
張貼留言